Trending...
- Update Any Sign Instantly with Santek EZ Sign NFC: Ultra-Slim 4-Color E-Paper Display - 940
- New Book "Curing Racism" Offers Hopeful Path to Healing America's Deepest Divide
- Hypnotic Hijinks of HypnoMarc Rolls into Sunnyvale for One Night Only
IGH Naturals has initiated a clinical trial to evaluate Humolyte®, an oral solution aimed at reducing chemotherapy-related side effects and improving supportive care in oncology.
SACRAMENTO, Calif. - Californer -- Sacramento, CA — IGH Naturals, a leader in innovative hydration and recovery solutions, has begun enrollment of patients in a clinical trial evaluating the efficacy of its flagship product, Humolyte®, in alleviating common and debilitating side effects experienced by chemotherapy patients. The study is being conducted by a clinical research organization in India with multiple clinical sites and hospitals participating.
The study, which has received all necessary regulatory approvals, will enroll approximately 38 patients undergoing chemotherapy treatment. Most of these patients are at a high risk for developing mucositis (oral ulcers) from the chemotherapy. The study's primary focus is to assess Humolyte's ability to reduce symptoms of gastrointestinal distress including diarrhea, vomiting, as well as minimization of the severity of oral mucositis (mouth sores)—symptoms that frequently compromise patient comfort, hydration, and quality of life.
More on The Californer
In addition to symptom relief, the trial will also evaluate Humolyte's potential to reduce the need for frequent intravenous (IV) hydration in chemotherapy patients, a breakthrough that could significantly enhance patient convenience and reduce healthcare costs.
"We are committed to advancing supportive care in oncology and currently, there are no effective solutions in the market that can reduce the symptoms of mucositis while enhancing hydration of these patients at home," said Dr. Sourabh Kharait, the Founder and CEO of IGH Naturals. "This study represents an important step in validating Humolyte as a safe, effective, and patient-friendly solution for managing chemotherapy-related complications."
The trial is expected to generate critical data on both the efficacy and tolerability of Humolyte, helping to inform future treatment protocols and improve overall patient outcomes. The study is expected to complete enrollment by spring of 2026.
For more information about the study or HuMOLYTE's commitment to innovative patient care solutions, please visit [www.humolyte.com] or contact:
The study, which has received all necessary regulatory approvals, will enroll approximately 38 patients undergoing chemotherapy treatment. Most of these patients are at a high risk for developing mucositis (oral ulcers) from the chemotherapy. The study's primary focus is to assess Humolyte's ability to reduce symptoms of gastrointestinal distress including diarrhea, vomiting, as well as minimization of the severity of oral mucositis (mouth sores)—symptoms that frequently compromise patient comfort, hydration, and quality of life.
More on The Californer
- Engaged at Any Age: 73-Year-Old Client Finds True Love Through Elite Asian Matchmaker
- California: CHP hits the Bay Area streets, enforces public safety through its crime suppression teams
- Launch of Professional Private Autopsy Services to Support Families, Professionals, and Researchers
- He Started a New Career at 77; Maybe Not His Last
- "The Art of Philanthropy" — A Year-Long Campaign Supporting the USO and Military Veterans
In addition to symptom relief, the trial will also evaluate Humolyte's potential to reduce the need for frequent intravenous (IV) hydration in chemotherapy patients, a breakthrough that could significantly enhance patient convenience and reduce healthcare costs.
"We are committed to advancing supportive care in oncology and currently, there are no effective solutions in the market that can reduce the symptoms of mucositis while enhancing hydration of these patients at home," said Dr. Sourabh Kharait, the Founder and CEO of IGH Naturals. "This study represents an important step in validating Humolyte as a safe, effective, and patient-friendly solution for managing chemotherapy-related complications."
The trial is expected to generate critical data on both the efficacy and tolerability of Humolyte, helping to inform future treatment protocols and improve overall patient outcomes. The study is expected to complete enrollment by spring of 2026.
For more information about the study or HuMOLYTE's commitment to innovative patient care solutions, please visit [www.humolyte.com] or contact:
Source: IGH Naturals
Filed Under: Health
0 Comments
Latest on The Californer
- WDBVC Launches PEER Up Grant Program to Empower Individuals with Disabilities
- $73.6 Million in Order Backlog Poised for Explosive Growth in 2026; Streamlined Share Structure: Cycurion, Inc. (N A S D A Q: CYCU) $CYCU
- Osric Langevin Unveils "Quantitative Trend" Framework for Multi-Asset Analysis in Q4 2025
- Experience Days Named Among the UK's Top Christmas Gifts
- New Free Educational Bingo Cards Make Learning English Fun for First Graders
- Wzzph Provides Stablecoin Trading Solutions for Latin American Traders Amid Digital Currency Policy Adjustments
- NaturismRE Calls for Recognition of AI as Sentient Kin in Global Bill of Rights
- California: Governor Newsom honors fallen San Bernardino County Sheriff's Deputy
- California: TOMORROW: Governor Newsom, Attorney General Bonta to announce legal action against Trump administration
- Guillermo X. Márquez Debuts True Crime and Supernatural Comedy Fiction Books
- HEY MEDIA COMPANIES! Want a Big '26? Check out all these great Moneymaking Projects and Promotions!
- Impact LA Responds to Food Crisis in Los Angeles
- THINKWARE Announces Halloween Deals on Popular Dash Cams
- City of Long Beach Facilities and Services Schedule for Election Day
- 20/20 Optometry of Silicon Valley Celebrates 25 Years of Vision Care for the Bay Area!
- PDS Plumbing & Air Honors Veterans with "Free Tune-Up & A Turkey" Giveaway
- PowerMy Introduces Independent Solar Diagnostics Platform to Help Homeowners Save Money
- Hiller's 2025 Flight Simulator Rally Inspires Golf Sim Revolution in Access and Training
- AgeImmune Announces the Launch of ImmuneG.I. — A Doctor-Formulated Herbal Supplement Supporting Gut and Digestive Wellness
- JetZero Commits to Landmark 30-Year Lease Agreement at Long Beach Airport